1. Home
  2. XP vs KYMR Comparison

XP vs KYMR Comparison

Compare XP & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo XP Inc.

XP

XP Inc.

N/A

Current Price

$13.12

Market Cap

10.2B

Sector

Finance

ML Signal

N/A

Logo Kymera Therapeutics Inc.

KYMR

Kymera Therapeutics Inc.

N/A

Current Price

$115.32

Market Cap

9.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
XP
KYMR
Founded
2001
2015
Country
Cayman Islands
United States
Employees
N/A
N/A
Industry
Investment Bankers/Brokers/Service
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.2B
9.0B
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
XP
KYMR
Price
$13.12
$115.32
Analyst Decision
Buy
Strong Buy
Analyst Count
12
24
Target Price
$19.94
★ $145.22
AVG Volume (30 Days)
★ 17.8M
882.9K
Earning Date
11-16-2026
10-29-2026
Dividend Yield
★ 4.83%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $39,211,000.00
Revenue This Year
$12.83
$153.48
Revenue Next Year
$11.88
N/A
P/E Ratio
$11.42
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$13.48
$63.69
52 Week High
$32.73
$142.92

Technical Indicators

Market Signals
Indicator
XP
KYMR
Relative Strength Index (RSI) 29.48 40.58
Support Level N/A $104.96
Resistance Level $17.12 $119.89
Average True Range (ATR) 0.63 7.15
MACD 0.03 -2.16
Stochastic Oscillator 4.34 1.47

Price Performance

Historical Comparison
XP
KYMR

About XP XP Inc.

XP Inc is a Cayman Island-based technology-driven financial services platform. It is a provider of low-fee financial products and services in Brazil. The company evaluates its business through a single segment such as monitoring operations, making decisions on fund allocation, and evaluating the performance. It generates revenue through the Brokerage commission. Geographically, the company derives maximum revenue from Brazil and also has its presence in other countries.

About KYMR Kymera Therapeutics Inc.

Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.

Share on Social Networks: